Disposition of 1815 shares by Dambkowski Carl of Apogee Therapeutics, at 22.86 subject to Rule 16b-3
| 26444HAL5 | 62.30 0.31 0.50% |
About 56% of 26444HAL5's investor base is looking to short. The analysis of the overall prospects from investing in DUK 3 15 DEC 51 suggests that many traders are, at the present time, alarmed. The current market sentiment, together with 26444HAL5's historical and current headlines, can help investors time the market. In addition, many technical investors use 26444HAL5 bond news signals to limit their universe of possible portfolio assets.
26444HAL5 |
Filed transaction by Apogee Therapeutics, Common Officer Chief Medical Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
26444HAL5 Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 26444HAL5 bond to make a market-neutral strategy. Peer analysis of 26444HAL5 could also be used in its relative valuation, which is a method of valuing 26444HAL5 by comparing valuation metrics with similar companies.
Peers
26444HAL5 Related Equities
| EDN | Empresa Distribuidora | 2.37 | ||||
| SPHR | Sphere Entertainment | 0.78 | ||||
| PRKS | United Parks | 0.62 | ||||
| UUGWF | United Utilities | 0.00 |
Other Information on Investing in 26444HAL5 Bond
26444HAL5 financial ratios help investors to determine whether 26444HAL5 Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 26444HAL5 with respect to the benefits of owning 26444HAL5 security.